{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T01:46:52Z","timestamp":1771724812082,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.clinthera.2011.08.012","type":"journal-article","created":{"date-parts":[[2011,10,21]],"date-time":"2011-10-21T14:25:11Z","timestamp":1319207111000},"page":"1503-1514","source":"Crossref","is-referenced-by-count":11,"title":["Effect of Vicriviroc With or Without Ritonavir on Oral Contraceptive Pharmacokinetics: A Randomized, Open-Label, Parallel-Group, Fixed-Sequence Crossover Trial in Healthy Women"],"prefix":"10.1016","volume":"33","author":[{"given":"Claudia","family":"Kasserra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barrie","family":"March","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"O'Mara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.08.012_bib1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1086\/518797","article-title":"Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211","volume":"196","author":"Gulick","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2011.08.012_bib2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1086\/650342","article-title":"Vicriviroc in combination therapy with an optimized regimen for experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial","volume":"201","author":"Suleiman","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2011.08.012_bib3","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1128\/AAC.49.12.4911-4919.2005","article-title":"Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1","volume":"49","author":"Strizki","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.08.012_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","article-title":"Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents","volume":"35","author":"Hsu","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2011.08.012_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1742-7843.2006.pto_249.x","article-title":"Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro","volume":"98","author":"Granfors","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2011.08.012_bib6","series-title":"Poster presented at: Third International AIDS Society Conference on HIV Pathogenesis and Treatment","article-title":"Similar increase in SCH 417690 plasma exposure with coadministration of varying doses of ritonavir in healthy volunteers","author":"Seiberling","year":"2005"},{"key":"10.1016\/j.clinthera.2011.08.012_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00003088-200746020-00003","article-title":"Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug","volume":"46","author":"Zhang","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2011.08.012_bib8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.steroids.2003.08.003","article-title":"All progestins are not created equal","volume":"68","author":"Stanczyk","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.clinthera.2011.08.012_bib9","series-title":"Ortho-Novum tablets (norethindrone\/ethinyl estradiol) [prescribing information]","year":"2009"},{"key":"10.1016\/j.clinthera.2011.08.012_bib10","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/dmd.30.7.795","article-title":"CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes","volume":"30","author":"Luo","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2011.08.012_bib11","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1124\/dmd.107.016089","article-title":"Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions","volume":"35","author":"Dixit","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2011.08.012_bib12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/jbt.20058","article-title":"Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers","volume":"19","author":"Smith","year":"2005","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1016\/j.clinthera.2011.08.012_bib13","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00526-07","article-title":"Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects","volume":"51","author":"Liu","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.08.012_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2125.1998.00749.x","article-title":"Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers","volume":"46","author":"Ouellet","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.08.012_bib15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/135965350801300415","article-title":"Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women","volume":"13","author":"Sekar","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.clinthera.2011.08.012_bib16","series-title":"HIV in the United States","year":"2009"},{"key":"10.1016\/j.clinthera.2011.08.012_bib17","first-page":"1","article-title":"Use of contraception and use of family planning services in the United States: 1982-2002","volume":"10","author":"Mosher","year":"2004","journal-title":"Adv Data"},{"key":"10.1016\/j.clinthera.2011.08.012_bib18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00228-003-0690-3","article-title":"Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals","volume":"59","author":"Galteau","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.08.012_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/00912700222011139","article-title":"Effect of rofecoxib on the pharmacokinetics of chronically administered oral contraceptives in healthy female volunteers","volume":"42","author":"Schwartz","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.08.012_bib21","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1128\/AAC.01005-06","article-title":"Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects","volume":"51","author":"Reddy","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.08.012_bib22","series-title":"Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products: general considerations","year":"2003"},{"key":"10.1016\/j.clinthera.2011.08.012_bib23","series-title":"Norvir (ritonavir) soft gelatin [full prescribing information]","year":"2010"},{"key":"10.1016\/j.clinthera.2011.08.012_bib24","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/clpt.2008.102","article-title":"Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II","volume":"84","author":"Kharasch","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2011.08.012_bib25","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s002280050545","article-title":"Neither dapsone hydroxylation nor cortisol 6\u03b2-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors","volume":"54","author":"Gass","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.08.012_bib26","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0091270003251864","article-title":"Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone","volume":"43","author":"Greenblatt","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.08.012_bib27","series-title":"Poster presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Similar increase in SCH 417690 plasma exposure with coadministration of varying doses of ritonavir in healthy volunteers","author":"Seiberling","year":"2005"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811005509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811005509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T17:28:18Z","timestamp":1686418098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811005509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0149291811005509"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.08.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}